Expert Reviews in Molecular Medicine: http://www.expertreviews.org/
DOI: 10.1017/S1462399407000476; 15 October 2007
Mandi Murph and Gordon B. Mills (2007) Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev. Mol. Med. Vol. 9, Issue 28, DOI: 10.1017/S1462399407000476

Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression

Mandi Murph ^a1 and Gordon B. Mills ^{a1 c1}

^a1 Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

^c1 Corresponding author: Mandi Murph, Department of Systems Biology, Unit 950, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. Tel: +1 713 563 4225; Fax: +1 713 563 4235; E-mail: mmmurph@mdanderson.org

The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.

Full text online (purchase or subscribe through Cambridge Journals Online)

| home | search | glossary | links | sitemap | contact |

Expert Reviews in Molecular Medicine © Cambridge University Press ISSN 1462-3994 (Disclaimer and copyright)
Editorial Office: Centre for Applied Research in Educational Technologies (CARET), 1st Floor, 16 Mill Lane, Cambridge, CB2 1SB, UK. Tel: +44 (0)1223 765 375; Fax: +44(0)1223 765 505; E-mail: ermm@caret.cam.ac.uk